Share Buyback
Summary by AI BETAClose X
EKF Diagnostics Holdings plc
(“EKF” or the “Company”)
Share Buyback
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that it has purchased a total of 80,000 of its ordinary shares of 1p each in the capital of the Company (“Ordinary Shares”) at a weighted average price of 25p pence per share. The purchased shares will be cancelled.
Aggregated information
|
Date of purchase |
25 September 2026 |
|
Number of Ordinary Shares purchased |
80,000 |
|
Highest price paid per Ordinary Share |
25p |
|
Lowest price paid per Ordinary Share |
25p |
|
Volume weighted average price paid |
25p |
Transaction details
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation) (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018), a detailed breakdown of individual trades is available below:
|
Number of Ordinary Shares purchased |
Transaction price (GBp) |
Time of transaction |
Trading venue |
|
40,000 |
25p |
15:21:53 |
AIMX |
|
40,000 |
25p |
15:38:11 |
AIMX |
Total voting rights
Following the purchase and after the cancellation of the shares becomes effective, the Company's total issued share capital will consist of 428,073,112 Ordinary Shares. There are no shares held in treasury. Therefore, the total number of Ordinary Shares carrying voting rights will be 428,073,112. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).
The person responsible for arranging the release of this Announcement
on behalf of the Company is Julian Baines, Executive Chair.
|
EKF Diagnostics Holdings plc |
|||
|
Julian Baines, Executive Chair |
via Walbrook PR |
||
|
Gavin Jones, Chief Executive Officer |
|
||
|
Singer Capital Markets (Nominated Adviser & Broker) |
Tel: +44 (0)20 7496 3000 |
||
|
Jen Boorer / Russell Cook / Patrick Weaver |
|
||
|
|
|
||
|
Walbrook PR Limited |
Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com |
||
|
Paul McManus / Alice Woodings |
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
||
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is an AIM-listed global diagnostics business focussed on:
|
● |
Point-of-Care analysers in the key areas of Hematology and Diabetes |
|
● |
Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications. |
EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 29 minutes ago Prudential
- 41 minutes ago Vanquis Banking Group 20
- 3 hours ago Frasers Group
- 3 hours ago Cavendish Financial
- 3 hours ago Diaceutics